David Feldman

Publications

• A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Srinivas S, Feldman D. Anticancer Res. 2009; 29 (9): 3605-10
• Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Malloy PJ, Wang J, Srivastava T, Feldman D. Mol Genet Metab. 2009
• Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Krishnan A, Feldman D. Endocr Relat Cancer. 2009
• Modulation of vitamin d receptor activity by the corepressor hairless: differential effects of hairless isoforms. Malloy PJ, Wang J, Jensen K, Feldman D. Endocrinology. 2009; 150 (11): 4950-7
• Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D. Endocrinology. 2009
• Unraveling insulin-like growth factor binding protein-3 actions in human disease. Jogie-Brahim S, Feldman D, Oh Y. Endocr Rev. 2009; 30 (5): 417-37
• Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD. Prostate. 2009; 69 (7): 719-26
• Hereditary vitamin D resistant rickets: identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. Ma NS, Malloy PJ, Pitukcheewanont P, Dreimane D, Geffner ME, Feldman D. Bone. 2009; 45 (4): 743-6
• Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl DM, Feldman D. Int J Cancer. 2009; 124 (9): 2050-9
• Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Malloy PJ, Peng L, Wang J, Feldman D. Endocrinology. 2009; 150 (4): 1580-7
• Inactivation of the human vitamin D receptor by caspase-3. Malloy PJ, Feldman D. Endocrinology. 2009; 150 (2): 679-86
• Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 935-40
• The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Peng L, Wang J, Malloy PJ, Feldman D. Int J Cancer. 2008; 122 (3): 558-66
• Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Nutr Rev. 2007; 65 (8 Pt 2): S113-5
• Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Krishnan AV, Swami S, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Nutr Rev. 2007; 65 (8 Pt 2): S121-3
• Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D. J Steroid Biochem Mol Biol. 2007; 103 (3-5): 694-702
• Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. J Nutr. 2007; 137 (1 Suppl): 205S-210S
• A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Malloy PJ, Wang J, Peng L, Nayak S, Sisk JM, Thompson CC, Feldman D. Arch Biochem Biophys. 2007; 460 (2): 285-92
• Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions. Wang J, Malloy PJ, Feldman D. J Biol Chem. 2007; 282 (35): 25231-9
• Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D. J Bone Miner Res. 2007: 22 Suppl 2 V74-80
• Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Moreno J, Krishnan AV, Peehl DM, Feldman D. Anticancer Res. 2006 Jul-Aug; 26 (4A): 2525-30
• Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Peng L, Malloy PJ, Wang J, Feldman D. Endocrinology. 2006; 147 (10): 4599-607
• Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. Mol Cancer Ther. 2006; 5 (6): 1539-49
• Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ. Mol Cancer Ther. 2006; 5 (8): 2078-85
• Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Srinivas S, Krishnan AV, Colocci N, Feldman D. Urology. 2006; 67 (5): 1001-6
• Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Nonn L, Peng L, Feldman D, Peehl DM. Cancer Res. 2006; 66 (8): 4516-24
• Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). Tsai CJ, Cohn BA, Cirillo PM, Feldman D, Stanczyk FZ, Whittemore AS. Cancer Causes Control. 2006; 17 (10): 1237-44
• Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Cancer Res. 2005; 65 (17): 7917-25
• Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. Whittemore AS, Cirillo PM, Feldman D, Cohn BA. J Urol. 2005; 174 (3): 872-6; discussion 876
• Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Swami S, Krishnan AV, Peehl DM, Feldman D. Mol Cell Endocrinol. 2005; 241 (1-2): 49-61
• Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. Moreno J, Krishnan AV, Feldman D. J Steroid Biochem Mol Biol. 2005; 97 (1-2): 31-6
• Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs. Liu Y, Shen Q, Malloy PJ, Soliman E, Peng X, Kim S, Pike JW, Feldman D, Christakos S. J Bone Miner Res. 2005; 20 (9): 1680-91
• Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Malloy PJ, Xu R, Peng L, Peleg S, Al-Ashwal A, Feldman D. Endocrinology. 2004; 145 (11): 5106-14
• Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, Halpern J, Balise RR, West DW, Paffenbarger RS, Whittemore AS. Cancer Epidemiol Biomarkers Prev. 2004; 13 (8): 1325-30
• Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM. Mol Cell Endocrinol. 2004; 221 (1-2): 67-74
• A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. Malloy PJ, Xu R, Cattani A, Reyes L, Feldman D. J Bone Miner Res. 2004; 19 (6): 1018-24
• Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Prostate. 2004; 59 (3): 243-51
• Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Peng L, Malloy PJ, Feldman D. Mol Endocrinol. 2004; 18 (5): 1109-19
• Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. Peehl DM, Feldman D. J Steroid Biochem Mol Biol. 2004; 92 (4): 307-15
• Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D. J Steroid Biochem Mol Biol. 2004; 92 (3): 131-41
• Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM. Cancer Epidemiol Biomarkers Prev. 2003; 12 (1): 23-7
• The role of vitamin D and retinoids in controlling prostate cancer progression. Peehl DM, Feldman D. Endocr Relat Cancer. 2003; 10 (2): 131-40
• Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. Peehl DM, Krishnan AV, Feldman D. J Nutr. 2003; 133 (7 Suppl): 2461S-2469S
• Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Breast Cancer Res Treat. 2003; 80 (1): 49-62
• The role of vitamin D in prostate cancer. Krishnan AV, Peehl DM, Feldman D. Recent Results Cancer Res. 2003: 164 205-21
• A low-calcemic vitamin D analog (Ro 25-4020) inhibits the growth of LNCaP human prostate cancer cells with increased potency by producing an active 24-oxo metabolite (Ro 29-9970). Swami S, Zhao XY, Sarabia S, Siu-Caldera ML, Uskokovic M, Reddy SG, Feldman D. Recent Results Cancer Res. 2003: 164 349-52
• Hereditary 1,25-Dihydroxyvitamin D-resistant rickets. Malloy PJ, Feldman D. Endocr Dev. 2003: 6 175-99
• Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. Krishnan AV, Peehl DM, Feldman D. J Cell Biochem. 2003; 88 (2): 363-71
• A novel nonsense mutation in the ligand binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. Malloy PJ, Zhu W, Bouillon R, Feldman D. Mol Genet Metab. 2002; 77 (4): 314-8
• A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Malloy PJ, Xu R, Peng L, Clark PA, Feldman D. Mol Endocrinol. 2002; 16 (11): 2538-46
• Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. Peehl DM, Seto E, Hsu JY, Feldman D. J Urol. 2002; 168 (4 Pt 1): 1583-8
• A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D. Endocrinology. 2002; 143 (5): 1889-900
• The role of vitamin D in prostate cancer. Zhao XY, Feldman D. Steroids. 2001 Mar-May; 66 (3-5): 293-300
• A new enzyme-linked immunosorbant assay for the measurement of human vitamin D receptor. Swami S, Sarabia SF, Diamandis A, Mistry J, Khosravi J, Feldman D. Bone. 2001; 28 (3): 319-26
• Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. Boyle BJ, Zhao XY, Cohen P, Feldman D. J Urol. 2001; 165 (4): 1319-24
• Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Hsu JY, Feldman D, McNeal JE, Peehl DM. Cancer Res. 2001; 61 (7): 2852-6
• Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. Krishnan AV, Swami S, Feldman D. J Steroid Biochem Mol Biol. 2001; 77 (1): 29-37
• A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets. Malloy PJ, Zhu W, Zhao XY, Pehling GB, Feldman D. Mol Genet Metab. 2001; 73 (2): 138-48
• Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Peehl DM, Seto E, Feldman D. Urology. 2001; 58 (2 Suppl 1): 123-6
• Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. J Clin Endocrinol Metab. 2001; 86 (8): 3568-73
• The development of androgen-independent prostate cancer. Feldman BJ, Feldman D. Nat Rev Cancer. 2001; 1 (1): 34-45
• 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Sung V, Feldman D. Mol Cell Endocrinol. 2000; 164 (1-2): 133-43
• 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Swami S, Krishnan AV, Feldman D. Clin Cancer Res. 2000; 6 (8): 3371-9
• 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Zhao XY, Peehl DM, Navone NM, Feldman D. Endocrinology. 2000; 141 (7): 2548-56
• Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Nat Med. 2000; 6 (6): 703-6
• Vitamin D resistance. Malloy PJ, Feldman D. Am J Med. 1999; 106 (3): 355-70
• Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Ly LH, Zhao XY, Holloway L, Feldman D. Endocrinology. 1999; 140 (5): 2071-6
• PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. Chen NG, Sarabia SF, Malloy PJ, Zhao XY, Feldman D, Reaven GM. Biochem Biophys Res Commun. 1999; 263 (3): 718-22
• Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. J Urol. 1999; 162 (6): 2192-9
• Vitamin D, parathyroid hormone, and calcium: a complex regulatory network. Feldman D, Am J Med. 1999; 107 (6): 637-9
• Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Zhao XY, Ly LH, Peehl DM, Feldman D. Endocrinology. 1999; 140 (3): 1205-12
• The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. J Bone Miner Res. 1998; 13 (11): 1691-9
• Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) Gross C, Stamey T, Hancock S, Feldman D. J Urol. 1998; 159 (6): 2035-9; discussion 2039-40
• Hereditary 1,25-dihydroxyvitamin D-resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor. Zhu W, Malloy PJ, Delvin E, Chabot G, Feldman D. J Bone Miner Res. 1998; 13 (2): 259-64
• Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. Gross C, Musiol IM, Eccleshall TR, Malloy PJ, Feldman D. Biochem Biophys Res Commun. 1998; 242 (3): 467-73
• Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: the OFELY study. Eccleshall TR, Garnero P, Gross C, Delmas PD, Feldman D. J Bone Miner Res. 1998; 13 (1): 31-5
• 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. Musiol IM, Feldman D. Endocrinology. 1997; 138 (1): 12-8
• Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D. J Clin Invest. 1997; 99 (2): 297-304
• Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. McClure L, Eccleshall TR, Gross C, Villa ML, Lin N, Ramaswamy V, Kohlmeier L, Kelsey JL, Marcus R, Feldman D. J Bone Miner Res. 1997; 12 (2): 234-40
• Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. Zhao XY, Eccleshall TR, Krishnan AV, Gross C, Feldman D. Mol Endocrinol. 1997; 11 (3): 366-78
• 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY, Ly LH, Peehl DM, Feldman D. Endocrinology. 1997; 138 (8): 3290-8
• Vitamin D. D. Feldman, F. Glorieux, and J.W. Pike, editors.. Academic Press, Inc., San Diego. 1997
• The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. Harris SS, Eccleshall TR, Gross C, Dawson-Hughes B, Feldman D. J Bone Miner Res. 1997; 12 (7): 1043-8
• Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Prostate. 1996; 29 (1): 20-9
• The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. J Bone Miner Res. 1996; 11 (12): 1850-5
• A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. Lin NU, Malloy PJ, Sakati N, al-Ashwal A, Feldman D. J Clin Endocrinol Metab. 1996; 81 (7): 2564-9
• Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Skowronski RJ, Peehl DM, Feldman D. Endocrinology. 1995; 136 (1): 20-6
• Vitamin D and prostate cancer. Feldman D, Skowronski RJ, Peehl DM. Adv Exp Med Biol. 1995: 375 53-63
• Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Krishnan AV, Cramer SD, Bringhurst FR, Feldman D. Endocrinology. 1995; 136 (2): 705-12
• Oestrogen-binding protein in Candida albicans: antibody development and cellular localization by electron immunocytochemistry. Zhao X, Malloy PJ, Ardies CM, Feldman D. Microbiology. 1995: 141 ( Pt 10) 2685-92
• Estrogens in unexpected places: possible implications for researchers and consumers. Feldman D, Krishnan A. Environ Health Perspect. 1995: 103 Suppl 7 129-33
• Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. Madani ND, Malloy PJ, Rodriguez-Pombo P, Krishnan AV, Feldman D. Proc Natl Acad Sci U S A. 1994; 91 (3): 922-6
• Inhibition of aldosterone synthesis in rat adrenal cells by nicotine and related constituents of tobacco smoke. Skowronski RJ, Feldman D. Endocrinology. 1994; 134 (5): 2171-7
• Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Cancer Res. 1994; 54 (3): 805-10
• Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. Malloy PJ, Weisman Y, Feldman D. J Clin Endocrinol Metab. 1994; 78 (2): 313-6
• ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome with major diagnostic and therapeutic implications. Lieberman SA, Eccleshall TR, Feldman D. Eur J Endocrinol. 1994; 131 (1): 67-73
• Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Zhao X, Feldman D. Endocrinology. 1993; 132 (4): 1808-14
• Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Endocrinology. 1993; 132 (6): 2279-86
• Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid-binding protein. Malloy PJ, Zhao X, Madani ND, Feldman D. Proc Natl Acad Sci U S A. 1993; 90 (5): 1902-6
• Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Skowronski RJ, Peehl DM, Feldman D. Endocrinology. 1993; 132 (5): 1952-60
• Cyclic adenosine 3',5'-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. Krishnan AV, Feldman D. Mol Endocrinol. 1992; 6 (2): 198-206
• Chronic atypical seizure disorder and cataracts due to delayed diagnosis of pseudohypoparathyroidism. Faig JC, Kalinyak J, Marcus R, Feldman D. West J Med. 1992; 157 (1): 64-5
• Cloning and characterization of the gene encoding the ADP-ribosylation factor in Candida albicans. Denich KT, Malloy PJ, Feldman D. Gene. 1992; 110 (1): 123-8
• Activation of protein kinase-C inhibits vitamin D receptor gene expression. Krishnan AV, Feldman D. Mol Endocrinol. 1991; 5 (4): 605-12
• Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Anesth Analg. 1991; 73 (2): 204-8
• Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors. Krishnan AV, Feldman D. J Bone Miner Res. 1991; 6 (10): 1099-107
• Hereditary 1,25-dihydroxyvitamin D resistant rickets: molecular basis and implications for the role of 1,25(OH) 2D3 in normal physiology. Feldman D, Malloy PJ. Mol Cell Endocrinol. 1990; 72 (3): C57-62
• The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. Malloy PJ, Hochberg Z, Tiosano D, Pike JW, Hughes MR, Feldman D. J Clin Invest. 1990; 86 (6): 2071-9
• Steroid metabolism as a mechanism of escape from progesterone-mediated growth inhibition in Trichophyton mentagrophytes. Clemons KV, Stover EP, Schär G, Stathis PA, Chan K, Tökès L, Stevens DA, Feldman D. J Biol Chem. 1989; 264 (19): 11186-92
• Sequence and expression of human myosin alkali light chain isoforms. Wade R, Feldman D, Gunning P, Kedes L. Mol Cell Biochem. 1989; 87 (2): 119-36
• Characterization of an estrogen-binding protein in the yeast Candida albicans. Skowronski R, Feldman D. Endocrinology. 1989; 124 (4): 1965-72
• Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. Malloy PJ, Hochberg Z, Pike JW, Feldman D. J Clin Endocrinol Metab. 1989; 68 (2): 263-9
• Dermatophyte-hormone relationships: characterization of progesterone-binding specificity and growth inhibition in the genera Trichophyton and Microsporum. Clemons KV, Schär G, Stover EP, Feldman D, Stevens DA. J Clin Microbiol. 1988; 26 (10): 2110-5
• Modulation of 1,25-dihydroxyvitamin D3 receptor binding and action by sodium butyrate in cultured pig kidney cells (LLC-PK1). Costa EM, Feldman D. J Bone Miner Res. 1987; 2 (2): 151-9
• Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Chen TL, Aronow L, Feldman D. Endocrinology. 1977; 100 (3): 619-28